Document Detail

Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
MedLine Citation:
PMID:  2093018     Owner:  NLM     Status:  MEDLINE    
A total of 143 patients with peptic ulceration of the duodenum, stomach and oesophagus who did not respond to 3 or more months of high-dose treatment with ranitidine, 450 mg or more daily, were treated with oral omeprazole, 40 mg daily. In 94% of the patients, ulcers healed within 2-8 weeks. After healing, 133 patients underwent long-term maintenance treatment with omeprazole, 40 mg daily, for 1-5 years (continuing). During maintenance therapy with omeprazole, no endoscopically verified relapses occurred, and no drug-related adverse effects were seen. There were no significant changes in routine laboratory tests in any patient, including 27 with concomitant liver cirrhosis. Basal serum gastrin levels, which were already elevated by the previous high-dose ranitidine treatment, rose to 4 times normal levels after 4 months of treatment with omeprazole. Thereafter, no further increases in basal serum gastrin levels were observed, even after 5 years of administration. The volume density of argyrophilic cells in the oxyntic mucosa increased during omeprazole treatment, but no dysplasia of the gastric enterochromaffin-like cells was seen. In conclusion, omeprazole was highly effective in healing ranitidine-resistant peptic ulcers, and subsequent maintenance therapy with omeprazole, 40 mg daily, was found to be effective and safe over the period observed.
G H Brunner; R Lamberts; W Creutzfeldt
Related Documents :
3898348 - Ranitidine versus anticholinergic/antacid for duodenal ulcer. a randomized, endoscopica...
6088368 - Single blind comparative study of ranitidine and cimetidine in patients with gastric ul...
15984968 - A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobac...
2892768 - Nizatidine in the short-term treatment of duodenal ulcer--an italian multicenter study.
10392678 - Obesity and coronary artery surgery.
21485418 - Economic model for emergency use authorization of intravenous peramivir.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Digestion     Volume:  47 Suppl 1     ISSN:  0012-2823     ISO Abbreviation:  Digestion     Publication Date:  1990  
Date Detail:
Created Date:  1991-06-18     Completed Date:  1991-06-18     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0150472     Medline TA:  Digestion     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  64-8; discussion 76     Citation Subset:  IM    
Department of Gastroenterology and Hepatology, Medical School, Hannover, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Resistance
Esophagitis, Peptic / drug therapy*
Gastrins / blood
Omeprazole / adverse effects,  therapeutic use*
Peptic Ulcer / drug therapy*
Ranitidine / therapeutic use*
Time Factors
Reg. No./Substance:
0/Gastrins; 66357-35-5/Ranitidine; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The clinical safety of omeprazole.
Next Document:  Australian clinical trials of omeprazole in the management of reflux oesophagitis.